For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
Scope of the Report:
This report studies the Human Immunodeficiency Virus (HIV)-1 Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Immunodeficiency Virus (HIV)-1 Therapeutics market by product type and applications/end industries.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Immunodeficiency Virus (HIV)-1 Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
-Merck & Co., Inc. (U.S.)
-Bristol-Myers Squibb Company (U.S.)
-Boehringer Ingelheim GmbH (Germany)
-Genentech, Inc. (U.S.)
-Cipla, Inc. (India)
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
-Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
-Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
-Entry and Fusion Inhibitors
-Protease Inhibitors (PIs)
Market Segment by Applications, can be divided into